The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments. (Q46835852)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Elizabeth C de Lange

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

13

Meindert Danhof

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Paulien G M Ravenstijn

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Mario Merlini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Marjolijn Hameetman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Tracey K Murray

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Mark A Ward

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Hywel Lewis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Cathy Mottart

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Christine de Ville de Goyet

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Thomas Lemarchand

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Kristel van Belle

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Michael J O'Neill

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

13 November 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

Journal of Pharmacological and Toxicological Methods

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

114-130

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18155613%20AND%20SRC:MED&resulttype=core&format=json

The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in naive and MPTP parkinsonian monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

RITA--registry of industrial toxicology animal-data--guides for organ sampling and trimming procedures in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Experimental models of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Animal models of Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

New pharmacologic horizons in the treatment of Parkinson disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

A family of drug transporters: the multidrug resistance-associated proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

6-Hydroxydopamine-induced alterations in blood-brain barrier permeability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Neuroprotective therapy in Parkinson disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Parkinson's disease: mechanisms and models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

The role of drug transporters at the blood-brain barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Multidrug resistance in cancer: role of ATP-dependent transporters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Drug equilibration across the blood-brain barrier--pharmacokinetic considerations based on the microdialysis method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Blood-brain barrier dysfunction in parkinsonian midbrain in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Rotenone induces non-specific central nervous system and systemic toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Blood-brain barrier active efflux transporters: ATP-binding cassette gene family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Mechanisms of action of 6-hydroxydopamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Diagnosis and treatment of Parkinson disease: molecules to medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

P-Glycoprotein, a gatekeeper in the blood-brain barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Protective effect of melatonin on rotenone plus Ca2+-induced mitochondrial oxidative stress and PC12 cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Ca2+‐induced oxidative stress in brain mitochondria treated with the respiratory chain inhibitor rotenone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003

Variable effects of chronic subcutaneous administration of rotenone on striatal histology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2007.10.003